Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,301 shares of Castle Biosciences stock in a transaction on Monday, November 24th. The shares were sold at an average price of $38.39, for a total value of $49,945.39. Following the completion of the sale, the insider directly owned 77,694 shares of the company’s stock, valued at approximately $2,982,672.66. This represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 0.2%

Castle Biosciences stock traded up $0.07 during trading on Thursday, hitting $30.47. The company’s stock had a trading volume of 833,433 shares, compared to its average volume of 407,908. The stock’s fifty day moving average is $23.38 and its 200 day moving average is $26.23. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The stock has a market capitalization of $930.86 million, a price-to-earnings ratio of -46.17 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. As a group, equities research analysts predict that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CSTL. Summit Partners Public Asset Management LLC increased its position in Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after purchasing an additional 658,725 shares in the last quarter. SummitTX Capital L.P. raised its holdings in Castle Biosciences by 285.0% in the first quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock valued at $1,646,000 after buying an additional 49,623 shares during the period. Eventide Asset Management LLC acquired a new position in Castle Biosciences during the fourth quarter valued at approximately $11,864,000. KBC Group NV acquired a new position in Castle Biosciences during the first quarter valued at approximately $907,000. Finally, SG Americas Securities LLC grew its stake in Castle Biosciences by 1,051.8% during the first quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock worth $6,012,000 after buying an additional 223,624 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CSTL shares. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a report on Friday, May 29th. Roth Capital began coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target on the stock. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Finally, Canaccord Genuity Group dropped their price objective on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.00.

More Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth prospects and implies meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle’s latest quarterly performance exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the loss of $0.07 per share was narrower than the expected $0.41 loss. The results support the view that operating performance is improving, although the company remains unprofitable.
• Positive Sentiment: Wall Street sentiment remains generally favorable, with an overall “Moderate Buy” consensus rating and an average price target of approximately $42. Institutional investors and hedge funds own about 92.6% of outstanding shares, while several funds recently increased their positions.
• Negative Sentiment: Several Castle Biosciences insiders sold shares. Derek J. Maetzold sold more than 39,000 shares across August 4–5, COO Kristen Oelschlager sold 8,586 shares, and Tobin W. Juvenal also reported a sale. The transactions reduced the executives’ holdings and could weigh on sentiment, particularly following the stock’s recent strength. However, the sales were conducted under pre-arranged Rule 10b5-1 plans, making them a less decisive bearish signal than discretionary selling. Castle Biosciences insider sales filing

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.